Market Access 101

Understand what happens after approval. Learn how payers, HTA bodies, health systems, pricing, reimbursement, and evidence come together to determine patient access.

Alkemi

MARKET
ACCESS 101

Helping Patients Gain Access to New Therapies

A No-Jargon Guide to Market Access for Teams Who've Never Done This Before

Chapter 01

The short version

Market access is how your drug goes from "approved" to "available." Without it, patients can't get it, doctors won't prescribe it, and your revenue forecast is fiction. Expensive fiction.

Approval allows a therapy to be marketed. Access depends on decisions made by payers, health systems, Health Technology Assessment (HTA) bodies, and other stakeholders. A strong strategy prepares for those decisions well before launch.

Key takeaways
01

Approval does not automatically lead to broad or easy patient access.

02

Access decisions vary by payer, market, benefit type, and site of care.

03

Evidence, pricing, contracting, stakeholder engagement, and launch execution must work together.

04

The most useful access strategies begin early and focus on the decisions most likely to shape patient use.

Market Access 101  ·  Alkemi02
Chapter 02

What is market access?

Market access connects a therapy's clinical value with the coverage and reimbursement decisions that determine whether patients can receive it.
The work spans strategy, evidence, pricing, contracting, payer engagement, HTA, and launch preparation.

The aim is to anticipate the requirements and barriers in each priority market, then prepare the evidence, messages, tools, and capabilities needed to address them.

Who makes access decisions?

United States

In the United States, commercial health plans, Medicare plans, Medicaid programs, pharmacy benefit managers, health systems, and provider organizations may all influence access. Their roles differ depending on whether a therapy is covered under the pharmacy or medical benefit and where it is administered.

Outside the US

Outside the United States, national or regional HTA and reimbursement bodies often evaluate comparative clinical benefit, budget impact, and, in some markets, cost-effectiveness. Local treatment practice and the choice of comparator can strongly influence the outcome.

Market Access 101  ·  Alkemi03
Chapter 03

The Payer's Desk: Where Good Drugs Go to Get Complicated

So your drug got approved. The press release went out. The champagne was opened. Now comes the part where approval meets reality: payers decide whether patients can actually receive the therapy.

The clinical question is “Does the drug work?” The access question is “Is this drug worth paying for compared with other options?”
1

Will we cover it?

This is the formulary inclusion decision; whether the drug gets a yes or no.

2

Under what conditions?

This covers utilization management, such as prior authorization, step edits, and quantity limits.

3

How much will we pay?

This includes reimbursement and contracting; the financial case behind access.

If you're coming from a clinical development background, this probably feels like an alternate universe. In clinical trials, the question is "does the drug work?" In market access, the question is "is this drug worth it compared to everything else we could pay for?"

Welcome to market access.
Let's make it less terrifying.

Market Access 101  ·  Alkemi04
Chapter 04

The Landscape: A Field Guide to US Payers

US payers are not one audience. They are a fragmented mix of commercial insurers, PBMs, Medicare plans, Medicaid programs, employers, health systems, and government purchasers:

1

Commercial Payers: The Working-Age Gate

UnitedHealthcare, Aetna, Cigna, Blue Cross plans, and the rest. They cover the working-age population and their dependents. They make formulary decisions through pharmacy and therapeutics (P&T) committees. They care about clinical differentiation, cost, and budget impact. If you can prove your drug saves them money downstream (fewer hospitalizations, fewer ER visits, lower total cost of care) they'll listen. If you're asking for a premium based on clinical novelty, bring extra patience, and extra data.

2

Medicare (CMS): The Volume Play

Covers patients 65 and older plus some younger patients with disabilities. Medicare Part D covers outpatient drugs through plan sponsors. If your disease disproportionately affects older adults, Medicare is your biggest payer. Full stop. And Medicare Advantage plans (commercial insurers administering Medicare benefits) add another layer of decision-making. Their coverage decisions don't always mirror traditional Medicare. Welcome to the fun house.

Market Access 101  ·  Alkemi05
Chapter 04  ·  continued
3

Medicaid: 50 States, 50 Rules

Covers low-income patients. Administered state by state. Coverage policies vary. Reimbursement rates are often low. If your patient population skews toward Medicaid, plan accordingly; you're negotiating with 50 different entities, each with their own preferred drug lists and rebate expectations.

4

PBMs: The Power Brokers

Express Scripts, CVS Caremark, OptumRx. Pharmacy benefit managers negotiate rebates and manage formularies on behalf of commercial and Medicare Part D plans. Your contracting strategy with PBMs directly affects your net price and formulary position. Think of PBMs as the middlemen who control the cash register. Love them or hate them (and plenty of people in pharma have opinions) they are gatekeepers you have to work with.

Ignoring PBMs is like ignoring gravity.
You can try, but the outcome is predictable.

Market Access 101  ·  Alkemi06
Chapter 05

The Gatekeepers: Access Barriers and Triggers

Payers don't say "yes" or "no." They say "yes, but." And the "but" is utilization management. Here's the lineup:

Prior Authorization (PA)

Before a patient can fill a prescription, the prescriber has to get approval from the payer. PA adds friction, delays treatment, and causes some patients to abandon therapy altogether. If your drug faces PA, your adherence numbers will take a hit. We've seen high abandonment rates on drugs with heavy PA requirements. That's patients who qualified, got prescribed, and then didn't get treated, because the paperwork was too much.

Step Edits

The patient has to try and fail on a less expensive therapy before the payer will cover yours. If there are cheap generics in your therapeutic area, expect step edits. This is the "prove the cheap stuff doesn't work" barrier. It protects the payer's budget. It frustrates your prescribers. And it's entirely predictable based on your competitive landscape.

Quantity Limits

The payer restricts how much of the drug a patient can get per fill. Usually tied to the labeled dosing schedule, but sometimes tighter.

Tier Placement

Where your drug sits on the formulary affects patient cost-sharing. Higher tier means higher copay means lower adherence means lower revenue. The domino effect is real and measurable.

What most companies miss

Here's the thing most companies miss: none of these barriers are arbitrary. They're the payer's direct response to their assessment of your drug's value. If your drug is clearly differentiated with strong evidence, barriers come down. If you're entering a competitive market with marginal differentiation and a premium price, barriers go up. The barriers are the grade on your homework. The evidence was the homework.

Market Access 101  ·  Alkemi07
Chapter 06

The Ex-US World: Different Rules, Same Stakes

Health Technology Assessment (HTA) is how most developed countries outside the US decide whether to reimburse a new drug. HTA bodies like NICE (UK), G-BA (Germany), HAS (France), CDA-AMC (Canada), and the new EU Joint Clinical Assessment all evaluate clinical effectiveness and (in many cases) cost-effectiveness.

What HTA bodies typically want to see:

01

Comparative effectiveness data against the relevant comparator. Against the relevant comparator. Against the relevant comparator. We said it three times because this is where companies stumble the most. Placebo-controlled data might get you through FDA. NICE wants to see you against the drug that's already being used.

02

Health-related quality of life data using validated instruments. EQ-5D is the gold standard for cost-utility analysis. If your Phase 3 collected a disease-specific instrument and no EQ-5D, you're going to have a very long meeting in London. Or Paris. Or Ottawa.

03

A cost-effectiveness model showing the incremental cost per QALY gained. This is the math that determines whether your drug is "cost-effective" in a given market. Get it wrong and you get a "no" with a detailed rejection letter. Get it right and you get access to 60+ million patients in the UK alone.

04

A budget impact analysis that shows the financial impact of adding your drug to the formulary over 3-5 years.

All of these requirements are knowable in advance. Published. Documented. Available on NICE's website, in G-BA's procedural guidance, in CADTH's methods manual. The information is there if you look for it before your Phase 3 protocol locks. Every company that gets a rejection from an HTA body had access to the same guidance. They either didn't read it or didn't act on it.

Market Access 101  ·  Alkemi08
Chapter 07

What belongs in a market access strategy?

A market access strategy should be clear about one thing: what access do we want, and what has to happen to get it? It should address priority payer and HTA stakeholders, likely coverage requirements, evidence needs, value messages, pricing and contracting choices, engagement plans, field tools, and launch milestones.

The strategy should also reflect how patients move through care. Testing, diagnosis, referrals, treatment setting, benefit design, and provider workflow can create access barriers even after a payer has issued a positive policy.

When should market access work begin?

Early planning allows payer and HTA needs to inform evidence generation and product strategy. Before Phase 3, access input can help shape comparators, endpoints, patient populations, and economic data collection. Closer to launch, the focus expands to pricing, submissions, payer engagement, field readiness, account planning, and barrier tracking.

The exact timeline depends on the therapy and market. The principle is consistent: begin early enough for access requirements to influence decisions, not simply assess them after they are fixed.

Market Access 101  ·  Alkemi09
Chapter 08

How Alkemi Helps

Alkemi helps life sciences companies build and execute market access strategies from development through launch. We assess the landscape, define the desired access position, identify evidence and stakeholder needs, and translate the strategy into practical plans for pricing, payer engagement, submissions, field teams, and launch readiness. Alkemi also has extensive experience supporting first-time launches via retained VP-level access strategy support.

Our work gives teams a clear view of what decisions are coming, where the risks are, and what you need to do next.

The Retainer Question: Hire vs. Outsource?

A question we hear from biotech CEOs and CCOs: "Should I hire a full-time VP of Market Access, or can I outsource this?"

18+

Months from launch

You probably don't need a full-time resource yet. What you need is a strategic partner who can help you build the evidence plan, start the payer engagement process, and set up the infrastructure. A fractional market access lead; a senior, experienced leader working on a retainer basis gives you strategic oversight without a $400,000+ salary and benefits package sitting idle.

12

Months from launch

You probably need both. An internal resource who will own the function long-term, and an external partner who can help them ramp up fast. The external partner brings pattern recognition; they've seen 20 launches and they know which mistakes to avoid. The internal person brings institutional knowledge and long-term accountability.

6

Months from launch

You're late. It's recoverable, but everything is going to cost more and move faster than it should. We've been in this situation with clients. It works, but nobody enjoys it. Do yourself a favor and call earlier.

Market Access 101  ·  Alkemi10
Chapter 09

FAQs

How long does it take to get payer coverage in the US?

For commercial payers, P&T committee reviews typically happen quarterly and initial decisions can take 3-6 months post-approval. Medicare Part D plans update formularies annually (though midyear changes can occur in certain instances). Full commercial coverage build-out (i.e. getting your drug on most major formularies with reasonable access) typically takes 12-18 months.

Plan for the long game. Your launch-week revenue is a rounding error compared to Year 2.

Can we talk to payers before our drug is approved?

Yes. And you should. In the US, pre-approval information exchange (PIE) allows manufacturers to share certain information with payers before FDA approval. Early payer engagement is one of the highest-value activities you can do. It costs relatively little, it gives you intelligence you can't get any other way, and it signals to payers that you take their perspective seriously. We've run pre-approval payer advisory boards that fundamentally changed a company's pricing strategy.

A $50,000 advisory board that prevents a $200 million pricing mistake is the best ROI in pharmaceutical development.

Market Access 101  ·  Alkemi11
Chapter 09  ·  continued

We're a rare disease company. Do payers treat us differently?

Generally, yes. Payers understand that rare disease drugs will be expensive and that clinical trial data will be limited. They tend to be more flexible on evidence requirements, but they still want to see unmet need, meaningful clinical benefit, and a coherent value narrative. Patient advocacy is particularly powerful in rare disease. A strong patient community can make the burden of the disease impossible to ignore and sometimes influence decisions in ways an economic model cannot.

What does a fractional market access lead actually do?

A fractional market access lead is a senior, experienced person who works with your team on a part-time or retainer basis. They lead evidence planning, manage payer engagements, oversee vendor work, and keep all the moving pieces pointed in the same direction. Think of them as the general contractor for your access strategy; they've built the house before, they know which subcontractors to hire, and they know what the building inspector (the payer) is going to check.

What is the biggest mistake first-time launchers make?

Underestimating how long everything takes. Building payer relationships, generating evidence, running HTA submissions, negotiating contracts; each of these has its own timeline, and they don't run in parallel as neatly as your Gantt chart suggests.


The companies that launch well start 24-36 months before PDUFA.
The companies that struggle start 6-12 months before.
The math is simple. The discipline is hard.

Market Access 101  ·  Alkemi12

Let's Get You Ready

At Alkemi, we've helped a diverse range of biotech and pharma companies build market access strategies that held up when payers started asking hard questions. We're small enough that you'll work directly with senior executives who've done this before and experienced enough that we've seen and solved most of the problems you're about to encounter.

If you have a launch coming and aren’t sure where to start, we can help you build the plan. If you’re six months out and scrambling, we’ve been there too.